Relationship of the magnitude of member cost-share and medication persistence with newly initiated renin angiotensin system blockers

Medicine & Life Sciences

• Cost Sharing 93%
• Medication Adherence 68%
• Renin-Angiotensin System 64%
• Costs and Cost Analysis 38%
• Angiotensin Receptor Antagonists 34%
• Pharmacy 31%
• Angiotensin-Converting Enzyme Inhibitors 30%
• Confidence Intervals 27%
• Angiotensins 17%
• Prescriptions 12%
• Medication Systems 11%
• Cohort Studies 10%
• Odds Ratio 9%
• Hydrochlorothiazide 9%
• Statistical Models 8%
• Censuses 8%
• Antihypertensive Agents 7%
• Proportional Hazards Models 6%
• Income 6%
• Observational Studies 6%
• Chronic Disease 5%
• Logistic Models 5%
• Therapeutics 3%
• Health 3%
• Pharmaceutical Preparations 3%
• Population 3%

Social Sciences

• cost sharing 66%
• persistence 54%
• medication 52%
• costs 34%
• confidence 27%
• chronic condition 7%
• health plan 7%
• Chronic Diseases 6%
• household income 6%
• census 5%
• employer 4%
• logistics 4%
• coverage 4%
• drug 4%
• regression 3%
• management 2%
• time 2%

Chemical Compounds

• Angiotensin-Converting Enzyme Inhibitor 85%
• Angiotensin II 78%
• Angiotensin 39%
• Amount 26%
• Hydrochlorothiazide 21%
• Antihypertensive 18%
• Chemical Transformation 9%
• Drug 8%
• Time 5%